AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Stock analysts at HC Wainwright raised their FY2025 earnings estimates for shares of AngioDynamics in a research note issued to investors on Monday, April 7th. HC Wainwright analyst Y. Chen now expects that the medical instruments supplier will earn ($0.21) per share for the year, up from their prior forecast of ($0.38). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics' Q4 2025 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.28) EPS.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. The company's revenue was down 4.3% compared to the same quarter last year.
AngioDynamics Trading Down 2.7 %
Shares of ANGO stock traded down $0.26 during trading hours on Thursday, reaching $9.53. The company's stock had a trading volume of 70,267 shares, compared to its average volume of 564,352. AngioDynamics has a one year low of $5.47 and a one year high of $13.50. The firm's fifty day simple moving average is $9.78 and its 200 day simple moving average is $8.98. The stock has a market capitalization of $386.98 million, a P/E ratio of -1.69 and a beta of 0.52.
Institutional Trading of AngioDynamics
A number of hedge funds have recently bought and sold shares of ANGO. SBI Securities Co. Ltd. purchased a new stake in AngioDynamics during the fourth quarter valued at approximately $28,000. State Street Corp boosted its holdings in shares of AngioDynamics by 2.7% during the 3rd quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier's stock valued at $6,305,000 after purchasing an additional 21,218 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in AngioDynamics by 28.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock valued at $4,304,000 after buying an additional 123,271 shares in the last quarter. Barclays PLC increased its position in AngioDynamics by 81.0% in the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier's stock worth $651,000 after purchasing an additional 37,394 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of AngioDynamics by 3.2% during the 4th quarter. Bank of New York Mellon Corp now owns 122,676 shares of the medical instruments supplier's stock valued at $1,124,000 after buying an additional 3,815 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company's stock.
Insider Activity at AngioDynamics
In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the business's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.40% of the stock is currently owned by corporate insiders.
About AngioDynamics
(
Get Free Report)
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Featured Articles
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
